Figure 6. Myeloid‐specific Cripto deletion affects vascular remodeling.

• A
  Representative pictures of CD31 (red) immunostaining of Control and Cripto^My‐LOF TA sections at days 5 (left panel) and 30 (right panel) after single injury (CTX‐I).
• B–D
  Quantification of CD31⁺ capillary number per area (mm²; B), average of capillary cross‐sectional area (μm²; C), and percentage of small (< 20 μm²) and large (> 100 μm²) capillaries (D) in Control and Cripto^My‐LOF injured muscles at indicated time points after single injury (CTX‐I). Data are mean ± SEM (n = 5 biological replicates; *P < 0.05; **P < 0.01; ***P < 0.001, Student's t‐test).
• E
  Representative pictures of CD31 (red) immunostaining of Control and Cripto^My‐LOF TA sections at days 5 (left panel) and 30 (right panel) after re‐injury (CTX‐II).
• F
  Representative pictures of mdx‐Control and mdx‐Cripto^My‐LOF diaphragm sections immunostained with VEcad (red).
• G, H
  Quantification of CD31⁺ capillary number per area (mm²; G) and average of capillary cross‐sectional area (μm²; H) in Control and Cripto^My‐LOF injured muscles at the indicated time points after re‐injury (CTX‐II). Data are mean ± SEM (n = 6 biological replicates; *P < 0.05; ***P < 0.001, Student's t‐test).
• I, J
  Quantification of capillary number per area (mm²; I) and average of capillary cross‐sectional area (μm²; J) in mdx‐Control and mdx‐Cripto^My‐LOF diaphragm muscles. Data are mean ± SEM (n = 5 biological replicates; ***P < 0.001, Student's t‐test).

Data information: Nuclei were counterstained with DAPI (blue). Scale bar: 100 μm. Magnification of the boxes is 3.5×.